SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Pui C-H,Evans WE. Acute lymphoblastic leukemia. N Engl J Med. 1998; 339: 605615.
  • 2
    Nachman JB,Sather HN,Sensel MG, et al. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med. 1998; 338: 16631671.
  • 3
    Kantarjian H,Thomas D,O'Brien S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer. 2004; 101: 27882801.
  • 4
    Faderl S,Jeha S,Kantarjian HM. The biology and therapy of adult acute lymphoblastic leukemia. Cancer. 2003; 98: 13371354.
  • 5
    Larson RA. Recent clinical trials in acute lymphocytic leukemia by the Cancer and Leukemia Group B. Hematol Oncol Clin North Am. 2000; 14: 13671379.
  • 6
    Durrant IJ,Richards SM,Prentice HG,Goldstone AH. The Medical Research Council trials in adult acute lymphocytic leukemia. Hematol Oncol Clin North Am. 2000; 14: 13271352.
  • 7
    Gokbuget N,Hoelzer D,Arnold R, et al. Treatment of Adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL). Hematol Oncol Clin North Am. 2000; 14: 13071325.
  • 8
    Thiebaut A,Vernant JP,Degos L, et al. Adult acute lymphocytic leukemia study testing chemotherapy and autologous and allogeneic transplantation. A follow-up report of the French protocol LALA 87. Hematol Oncol Clin North Am. 2000; 14: 13531366.
  • 9
    Fielding AK,Richards SM,Chopra R, et al. Medical Research Council of the United Kingdom Adult ALL Working Party; Eastern Cooperative Oncology Group. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood. 2007; 109: 944950.
  • 10
    Tavernier E,Boiron JM,Huguet F, et al. GET-LALA Group; Swiss Group for Clinical Cancer Res. SAKK; Australasian Leukaemia and Lymphoma Group. Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial. Leukemia. 2007; 21: 19071914.
  • 11
    Garcia-Manero G,Thomas DA. Salvage therapy for refractory or relapsed acute lymphocytic leukemia. Hematol Oncol Clin North Am. 2001; 15: 163205.
  • 12
    Thomas DA,Kantarjian H,Smith TL, et al. Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy. Cancer. 1999; 86: 12161230.
  • 13
    George SL,Ochs JJ,Mauer AM,Simone JV. The importance of an isolated central nervous system relapse in children with acute lymphoblastic leukemia. J Clin Oncol. 1985; 3: 776781.
  • 14
    Jeha S,Kantarjian H. Clofarabine for the treatment of acute lymphoblastic leukemia. Exp Rev Anticancer Ther. 2007; 7: 113118.
  • 15
    Jeha S,Gandhi V,Chan KW, et al. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood. 2004; 103: 784789.
  • 16
    Cox DR,Snell EJ. The analysis of binary data. London, UK: Chapman & Hall; 1970: 3343.
  • 17
    Cox DR. Regression models and life tables. J Stat Soc B. 1972; 34: 187220.
  • 18
    Kurtzberg J,Ernst TJ,Keating MJ, et al. Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. J Clin Oncol. 2005; 23: 33963403.
  • 19
    DeAngelo DJ,Yu D,Johnson JL, et al. Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. Blood. 2007; 109: 51365142.
  • 20
    Ottmann OG,Druker BJ,Sawyers CL, et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood. 2002; 100: 19651971.
  • 21
    Ottmann O,Dombret H,Martinelli G, et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood. 2007; 110: 23092315.
  • 22
    Ottmann O,Kantarjian H,Larson R, et al. A Phase II study of nilotinib, a novel tyrosine kinase inhibitor administered to imatinib resistant or intolerant patients with chronic myelogenous leukemia (CML) in blast crisis (BC) or relapsed/refractory Ph+ acute lymphoblastic leukemia (ALL). Blood. 2006; 108: 1862.